Tepezza®
Teprotumumab-trbw · intravenous infusion
Injections & Implants
Approved uses
Thyroid eye disease, active
10 mg/kg IV once, then 20 mg/kg IV every 3 weeks for 7 additional infusions, 8 in total
Proptosis falls about 2.8 mm by week 24, with 83% reaching a response.
Thyroid eye disease, chronic and low activity
10 mg/kg IV once, then 20 mg/kg IV every 3 weeks for 7 additional infusions, 8 in total
In long-standing inactive disease proptosis improves 1.5 mm over placebo, about half the active-disease effect.
OFF-LABELNot in the FDA label for this product
Retreatment after nonresponse or disease flare
Second course of 8 infusions over 24 weeks, the OPTIC-X protocol
Open-label ext · n=13
Open-label extension of OPTIC, no control arm and very small numbers: of 8 initial responders who flared, 5 (62.5%) responded again on retreatment with a mean proptosis reduction of 1.9 mm (SD 1.2) from the extension baseline, and of 5 initial nonresponders retreated, 2 responded, 1 fell short at 1.5 mm, and 2 discontinued early. The 37 previously placebo-treated patients, whose median disease duration was 12.9 months versus 6.3 months in OPTIC, responded at 89.2%, which is what supports treating longer-duration disease. Mild hearing impairment recurred in 2 patients on retreatment.
Contraindications
None.
500 mg lyophilized powder in a single-dose vial, one vial per carton, 47.6 mg/mL after reconstitution with 10 mL Sterile Water for Injection
Fully human IgG1 monoclonal antibody that binds to the insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. Its mechanism of action in patients with Thyroid Eye Disease has not been fully characterized, and no formal pharmacodynamic studies have been conducted.
Warnings & Precautions
- Hearing impairment including hearing loss: May cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess hearing before, during, and after treatment and consider the benefit-risk of treatment with patients.
- Infusion reactions: Reported in approximately 4% of treated patients, during any infusion or within 1.5 hours after, usually mild or moderate and usually manageable with corticosteroids and antihistamines. If one occurs, interrupt or slow the infusion and use appropriate medical management; consider pre-medicating with an antihistamine, antipyretic, corticosteroid and/or giving all subsequent infusions at a slower rate.
- Inflammatory bowel disease: May cause an exacerbation of IBD, and IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, and discontinue if IBD exacerbation is suspected.
- Hyperglycemia: May occur; in premarketing trials 10% of patients had hyperglycemia, two-thirds of whom had preexisting diabetes or impaired glucose tolerance. Assess blood glucose and symptoms before infusion and continue to monitor during treatment. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving treatment, using medications if necessary.
- Encephalopathy: Reported during postapproval use; in some patients, symptoms improved after discontinuation and/or treatment for encephalopathy. Evaluate patients with signs or symptoms suggestive of encephalopathy, and if it is suspected, interrupt or discontinue TEPEZZA and treat as clinically appropriate.
Common Side Effects
The most common premarketing trial adverse reactions were muscle spasms (25%), nausea (17%), alopecia (13%), diarrhea (12%), fatigue (12%), hyperglycemia (10%), hearing impairment (10%; deafness, eustachian tube dysfunction, hyperacusis, hypoacusis, autophony and tinnitus), dysgeusia (8%), headache (8%), dry skin (8%), weight decreased (6%) and nail disorder (5%). In two postapproval trials, hearing impairment occurred in 19%. Menstrual disorders (amenorrhea, metrorrhagia, dysmenorrhea) were reported in approximately 23% (5 of 22) of menstruating women versus 4% (1 of 25) on placebo. Postmarketing reports include bowel perforation, exacerbation of inflammatory bowel disease, including in patients without a prior diagnosis, diabetic ketoacidosis, hyperosmolar hyperglycemic state, encephalopathy, and severe hearing impairment including hearing loss, which in some cases may be permanent.
Pregnancy: May cause fetal harm, based on animal findings and on IGF-1R inhibition, so it should not be used in pregnancy. Cynomolgus monkeys dosed at 2.8 times the maximum recommended human dose by AUC had a higher incidence of abortion, decreased fetal growth and placental size, and multiple external and skeletal abnormalities in every exposed fetus. Pregnancy test before starting and effective contraception before, during, and for 6 months after the last dose. If pregnancy occurs during treatment, discontinue TEPEZZA and advise the patient of the potential risk to the fetus.
Lactation: No information on presence in human milk, effects on the breastfed infant, or effects on milk production.
Safety and effectiveness not established in pediatric patients.